New research from Stockholm University and Karolinska Institutet shows that viruses interact with proteins in the biological fluids of their host which results in a layer of proteins on the viral surface. This coat of proteins makes the virus more infectious and facilitates the formation of plaques characteristic of neurodegenerative diseases such as Alzheimer’s disease.
Are viruses dead or alive? Well… both. Viruses can only reproduce inside living cells and exploit the cellular machinery of their host to their benefit. However, before entering a host cell, viruses are just nanometer-sized particles, very similar to artificial nanoparticles used in medical applications for diagnosis and therapy. Scientists from Stockholm University and Karolinska Institutet have found that viruses and nanoparticles share another important property; they both become covered by a layer of proteins when they encounter the biological fluids of their host before they find their target cell. This layer of proteins on the surface influence their biological activity significantly.
“Imagine a tennis ball falling into a bowl of milk and cereals. The ball is immediately covered by the sticky particles in the mix and they remain on the ball when you take it out of the bowl. The same thing happens when a virus gets in contact with blood or lung fluids that contain thousands of proteins. Many of these proteins immediately stick to the viral surface forming a so-called protein corona”, Kariem Ezzat of Stockholm University and Karolinska Institutet explains.
Kariem Ezzat and his colleagues studied the protein corona of respiratory syncytial virus (RSV) in different biological fluids. RSV is the most common cause of acute lower respiratory tract infections in young children worldwide, leading up to 34 million cases and 196,000 fatalities each year. “The protein corona signature of RSV in the blood is very different from that in lung fluids. It is also different between humans and other species such as rhesus macaque monkeys, which also can be infected with RSV”, Kariem Ezzat says. “The virus remains unchanged on the genetic level. It just acquires different identities by accumulating different protein coronae on its surface depending on its environment. This makes it possible for the virus to use extracellular host factors for its benefit, and we’ve shown that many of these different coronae make RSV more infectious.”
The researchers from Stockholm University and Karolinska Institutet have also found that viruses such as RSV and herpes simplex virus type 1 (HSV-1) can bind a special class of proteins called amyloid proteins. Amyloid proteins aggregate into plaques that play a part in Alzheimer’s disease where they lead to neuronal cell death. The mechanism behind the connection between viruses and amyloid plaques has been hard to find till now, but Kariem Ezzat and his colleagues found that HSV-1 is able to accelerate the transformation of soluble amyloid proteins into thread-like structures that constitute the amyloid plaques. In animal models of Alzheimer’s disease, they saw that mice developed the disease within 48 hours of infection in the brain. In absence of an HSV-1 infection the process normally takes several months.
“The novel mechanisms described in our paper can have an impact not only on understanding new factors determining how infectious a virus is, but also on devising new ways to design vaccines. In addition, describing a physical mechanism that links viral and amyloid causes of disease adds weight to the increasing research interest in the role of microbes in neurodegenerative disorders such as Alzheimer’s disease and opens up new avenues for treatments.”, Kariem Ezzat of Stockholm University and Karolinska Institutet says.
Learn more: Coat of proteins makes viruses more infectious and links them to Alzheimer’s disease
The Latest on: Neurodegenerative diseases
[google_news title=”” keyword=”neurodegenerative diseases” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Neurodegenerative diseases
- Discovery of new vascular cell type may pave way for novel strategies to treat cardiovascular diseaseson April 18, 2024 at 12:46 pm
Cardiovascular diseases, including stroke and myocardial infarction, are the world's leading causes of mortality, accounting for over 18 million deaths a year.
- Parkinson’s Disease Drug Tavapadon Significantly Improved Symptom Control, Cerevel Sayson April 18, 2024 at 7:37 am
A late-stage trial of Cerevel Therapeutic’s Parkinson’s disease drug showed a significant reduction in the time patients suffer from symptoms, the company said Thursday, the latest study indicating ...
- Molecular clean-up mechanism removes plaques in Alzheimer’s diseaseon April 17, 2024 at 7:00 am
Researchers have produced a monoclonal antibody capable of encouraging the breakdown of plaques associated with Alzheimer’s disease in mice. Researchers at the Washington School of Medicine in St.
- Medical Monday: Therapy Options for Those with Parkinson’s Diseaseon April 16, 2024 at 10:09 am
In this week's Medical Monday, we focus on some of the therapy options available for those who suffer from Parkinson's Disease.
- Labcorp launches blood test for neurodegenerative diseases detectionon April 16, 2024 at 6:39 am
G lobal life sciences company Labcorp has announced the first commercially available glial fibrillary acidic protein (GFAP) blood biomarker test in the US, offering a new tool for the early detection ...
- Jaya Biosciences Presents Updated Preclinical Data in Alzheimer’s Disease at the 45th SIMD Annual Meetingon April 16, 2024 at 5:57 am
During a podium presentation, Jaya Biosciences’ scientific founder and science advisory board chair, Professor Mark Sands, reported on recently updated human genetic analyses suggesting that ...
- One and done? Labcorp launches test for multiple brain disorderson April 15, 2024 at 3:44 pm
Laboratory Corp. of America Holdings introduced a glial fibrillary acidic protein blood-based test available commercially in the U.S. for the early detection of neurodegenerative diseases and brain ...
- Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Drawon April 15, 2024 at 4:00 am
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a ...
- Friends and Foes: Astrocytes as Disease Targetson April 10, 2024 at 7:25 am
A new platform for screening astrocyte reactivity helps researchers uncover potential therapeutic interventions to treat neurodegenerative conditions.
- Mitochondrial roles in antiviral immunity modify manifestations of neurological diseaseson April 8, 2024 at 5:35 am
Scientists report that a progressive neurodegenerative disease can be triggered by a viral infection. The mechanism relates to mitochondrial roles in antiviral defense mechanisms.
via Bing News